Single-Dose Antimalarial Compounds for Adherence and Resistance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antimalarial treatments, particularly Artemisinin-based Combination Therapies (ACTs), face challenges such as emerging resistance and low patient adherence due to daily dosing regimens, necessitating the development of effective and affordable single-dose antimalarial agents with new mechanisms of action.
Innovation Solution
Development of novel potent anti-malarial compounds of formula (I) and their pharmaceutical compositions, which can be administered in a single dose, targeting Plasmodium falciparum and Plasmodium vivax infections, with pharmacokinetic properties suitable for single-dose combination therapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Artemisinin-based Combination Therapy (ACT) is administered orally once or twice daily for three days, then the treatment targets the erythrocytic life cycle of the parasite effectively, but patient adherence is low and treatment complexity increases
Solution Approach 1:
The patent combines multiple antimalarial compounds with different pharmacokinetic profiles into a single fixed-dose combination tablet. This merging of multiple drugs into one formulation allows for simplified administration while maintaining the synergistic effects of combination therapy, directly addressing the adherence problem without sacrificing treatment effectiveness.
Solution Approach 2:
The patent designs the fixed-dose combination with compounds having complementary half-lives that achieve sustained therapeutic levels with single or limited dosing. The pharmacokinetic properties of the combined compounds create an extended action profile that maintains effective concentrations over the required treatment period, reducing dosing frequency while preserving reliability.
2Speed
If current ACT regimens are used, then fast onset of action is achieved, but emergence of resistance occurs in the Greater Mekong Sub-region
Solution Approach 1:
The patent creates a composite pharmaceutical formulation combining multiple antimalarial compounds with different mechanisms of action. This composite approach targets the parasite through multiple pathways simultaneously, making it harder for the parasite to develop resistance while maintaining the fast onset of action provided by the artemisinin component.
Solution Approach 2:
The fixed-dose combination incorporates compounds that target different stages and mechanisms of the parasite lifecycle. This multi-functionality ensures broad coverage against Plasmodium species while the diverse mechanisms of action reduce the likelihood of resistance development, addressing both speed and reliability concerns.
3Ease of operation
If single dose treatment is implemented, then patient adherence improves and operational challenges are addressed, but pharmacokinetic properties must be precisely optimized
Solution Approach 1:
The patent carefully selects and combines compounds with specific pharmacokinetic parameters (half-life, bioavailability, metabolic stability) to achieve the desired single-dose or limited-dose profile. By optimizing these parameters through molecular selection and formulation, the patent simplifies administration while managing the complexity of achieving sustained therapeutic levels.
Solution Approach 2:
The patent uses pharmacokinetic modeling and clinical trial data as intermediaries to bridge the gap between theoretical single-dose concepts and practical implementation. These intermediaries guide the optimization process, allowing systematic adjustment of dosing regimens based on observed drug levels and efficacy outcomes.
Data Source
AI summary
The present disclosure relates to compounds of formula (I) or a pharmaceutically acceptable salt thereof wherein R1 means a fluorine atom or a perhalogeno linear alkyl radical containing 1, 2 or 3 carbon atoms; R2 means a chlorine atom, a linear alkyl radical containing 1, 2 or 3 carbon atoms or a perhalogeno linear alkyl radical containing 1, 2 or 3 carbon atoms, and R means a hydrogen atom or a radical of formula (la). The present disclosure also relates to processes for their preparation as well their therapeutic uses, in particular such as for use in the treatment of malaria.